Mark Leonard Singleton Sells 5,479 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 5,479 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $9.79, for a total value of $53,639.41. Following the transaction, the chief financial officer now owns 131,963 shares of the company’s stock, valued at $1,291,917.77. This trade represents a 3.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Leonard Singleton also recently made the following trade(s):

• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The stock was sold at an average price of $10.19, for a total value of $66,214.62.

Bioventus Trading Down 3.0 %

BVS stock opened at $9.43 on Wednesday. The business has a fifty day moving average price of $10.12 and a 200 day moving average price of $11.01. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The stock has a market capitalization of $772.73 million, a price-to-earnings ratio of -15.46 and a beta of 0.86.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on BVS shares. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and upped their target price for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Monday, March 17th.

Institutional Trading of Bioventus

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Bioventus by 18.7% during the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after buying an additional 388,174 shares in the last quarter. Driehaus Capital Management LLC increased its position in Bioventus by 33.7% in the 4th quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company’s stock valued at $11,758,000 after acquiring an additional 282,341 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Bioventus in the third quarter worth about $3,092,000. American Century Companies Inc. lifted its position in shares of Bioventus by 38.7% during the fourth quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock worth $9,289,000 after purchasing an additional 246,645 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Bioventus by 38.8% during the third quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after purchasing an additional 189,216 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.